Dongwha Pharm's COVID-19 Treatment Candidate 'DW2008S' Selected for Government New Drug Development Project
[Asia Economy Reporter Lee Gwan-joo] Dong Wha Pharm announced on the 17th that the Phase 2 clinical trial of its COVID-19 treatment DW2008S has been selected as a new project in the 5th round of 2021 by the COVID-19 Therapeutics and Vaccine New Drug Development Project Group, and an agreement has been signed.
With this government project selection, Dong Wha Pharm will receive support to conduct a Phase 2 clinical trial evaluating the efficacy and safety of DW2008S compared to a placebo.
Dong Wha Pharm's COVID-19 treatment candidate DW2008S confirmed antiviral activity through cell experiments in April 2020. The Phase 2 clinical trial, approved by the Ministry of Food and Drug Safety in November 2020, is currently underway at nine clinical institutions nationwide, targeting patients with moderate symptoms.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- Samsung Enterprise Labor Union: "We Respect Court’s Injunction Decision... General Strike to Proceed on the 21st as Planned"
- "Was This Delicious Treat Enjoyed Only by Koreans?"... The K-Dessert Captivating Japan
- [Exclusive] With Budget Safeguard Gone, Digital Learning Center May Be Reduced or Disappear in Financially Weaker Local Governments
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
A Dong Wha Pharm official stated, “Dong Wha Pharm will devote more effort to developing treatments to support the rapid return to daily life for many suffering from COVID-19,” and added, “We will use the selection as a new drug development project in the 5th round as an opportunity to accelerate the development of the treatment.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
